1. Introduction
===============

Translation elongation factor 1A (eEF1A) is one of the core members of the elongation machinery providing high efficiency and processivity of the protein synthesis process in the eukaryotic cell ([@bib27]). eEF1A forms a ternary complex with aminoacyl-tRNA and GTP and delivers the correct aminoacyl-tRNA to the A site of mRNA programmed ribosome in the GTP hydrolysis-dependent mode. The GDP-bound form of eEF1A has been shown to interact with deacylated tRNA ([@bib29]) and can transport it to aminoacyl-tRNA synthetase as the tRNA recycling arm of a tRNA channelling cycle ([@bib30]).

It is believed that the translation function of eEF1A might be combined with its involvement in cytoskeletal network maintenance and various signalling pathways ([@bib18]). eEF1A has been shown to interact with phospholipase C-gamma1 (PLC-gamma1) ([@bib9; @bib17]) and non-receptor tyrosine kinase Txk of the Tec family ([@bib23]). Importantly, Txk can form a complex with poly(ADP-ribose) polymerase 1 and eEF1A to influence interferon-gamma gene transcription in Th1 cells. Recently [@bib19] identified eEF1A as a novel binding partner for Akt2 rho-associated kinase. In most cases it is not known whether interactions of eEF1A with protein kinase might lead to phosphorylation of eEF1A. Neither has the role of eEF1A in signal transduction pathways been identified.

In mammalian cells, two tissue- and development-specific isoforms, eEF1A1 and eEF1A2, are present. The expression of the 98% similar isoforms is mutually exclusive ([@bib16]). Interestingly, eEF1A2, which is present normally only in muscles and neurons, was recently associated with tumor development in tissues that normally express only eEF1A1 ([@bib3; @bib4]). How eEF1A2 isoform is involved in malignant transformation is not as yet understood. Since tyrosine kinases are prominent players in cancer development, direct comparison of the ability of eEF1A1 and eEF1A2 to be involved in phosphoTyr-specific signalling processes could help to interpret cancer-related properties of eEF1A2.

In this study, we compared for the first time the interactions of eEF1A1 and eEF1A2 with SH2 and SH3 domains of various signalling molecules. Contrary to eEF1A1, eEF1A2 was able to interact with SH2 domains of Grb2, RasGAP, Shc and Shp2 as well as with SH3 domains of Crk, Fgr, Fyn and PLC-gamma1. Both eEF1A1 and eEF1A2 formed complexes with SH2 domain of PLC-gamma1. *In vivo* interaction between endogenous eEF1A and tyrosine phosphatase Shp2 was confirmed in HEK293 cell line and tyrosine phosphorylation of eEF1A1 and eEF1A2 was demonstrated by Western blots with anti-phosphotyrosine-specific antibodies. Importantly, the level of phosphorylation of eEF1A2 was higher than eEF1A1 when isolated from tissues, and also when overexpressed in cells. Furthermore, the level of phosphorylation has been shown to be crucial for *in vitro* complex formation of eEF1A2 and SH2 domain of Shp2.

2. Materials and methods {#sec1}
========================

2.1. Cell lines and plasmid constructs
--------------------------------------

HEK293 cells were purchased from the American Type Culture Collection (Manassas, VA) and grown according to their instructions. To produce eEF1A1 and eEF1A2 stable cell lines pcDNA 3.1 eEF1A1 and eEF1A2 with the C-terminal His-tags were linearized by MunI and transfected in HEK293 cells using ExGene500 (Fermentas) according to manufacturer recommendations. G418 was used to select stable cell lines.

2.2. Bioinformatics
-------------------

ScanSite Program was used for bioinformatic identification of possible SH2 and SH3 domains binding sites within eEF1A1 and eEF1A2. ScanSite employs the matrix of selectivity values for amino acids at each position relative to an orienting residue as determined by the oriented peptide library technique ([@bib28]).

2.3. Purification of the eEF1A1 and eEF1A2 isoforms
---------------------------------------------------

eEF1A1 was purified from rabbit liver using a combination of the gel filtration, anion exchange, cation exchange and hydroxyapatite chromatographies as described previously ([@bib6]). eEF1A2 was isolated from rabbit muscles using the same procedure except the gel-filtration step was omitted in some cases. To confirm the biological activity of the isolated isoforms, the GDP/\[^3^H\]GDP exchange was carried out as in ([@bib8]).

2.4. Pull down assay
--------------------

Purified GST-SH2 and GST-SH3 domains of various signalling molecules were kindly provided by Prof. Ivan Gout (London, UK) ([@bib13]). In a pull down assay, 1.5 μg of GST, GST-SH2 or GST-SH3 domains fusion protein was incubated with glutathione-Sepharose 4B beads (Amersham Biosciences) for 2 h at 4 °C. The beads were then washed to remove unbound proteins and incubated at 4 °C for 3 h with 1.5 μg of purified eEF1A1 or eEF1A2. Non-specific interactions were removed by extensive washing and bound proteins eluted by boiling in Laemmli sample buffer. Eluted proteins were resolved by SDS-PAGE, transferred to polyvinylidene difluoride membrane, and detected by immunoblotting with specific antibodies.

2.5. Phosphatase treatment
--------------------------

Calf intestine alkaline phosphatase (CIAP) (Fermentas) has been used to dephosphorylate eEF1A1 and eEF1A2. The proteins were precipitated from the lysates of stable cell lines on NiNTA and extensively washed with 1× reaction buffer for CIAP (10 mM Tris--HCl (pH 7.5), 10 mM MgCl~2~), then 10 U of CIAP was added and reaction mix was incubated at 37 °C for 1 h. Thereafter the beads were washed two times with 1× reaction buffer and the proteins bound were eluted by boiling in Laemmli sample buffer.

For dephosphorylation of total protein fraction HEK293 cells overexpressing eEF1A1 or eEF1A2 were extracted with 1× CIAP reaction buffer. To facilitate lysis the cells were passed through a 20-gauge needle 20 times and whole cell extracts were centrifuged at 10,000 × *g* for 15 min at 4 °C. The supernatant was incubated with 10 U of CIAP at 37 °C for 1 h, in control samples sodium orthovanadate was added to final concentration 1 mM.

2.6. Immunoprecipitation
------------------------

HEK293 cells were treated under indicated conditions, then washed with ice-cold phosphate-buffered saline (PBS) and extracted with the lysis buffer containing 10 mM Tris--HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate and a mixture of protease inhibitors (Roche Applied Science). Whole cell extracts were centrifuged at 10,000 × *g* for 15 min at 4 °C. Endogenous protein complexes were immunoprecipitated from 0.5 mg of total cell lysates with corresponding antibodies (1 μg/probe) and immobilized on protein A-Sepharose beads (Amersham Biosciences). Immune complexes were washed three times with the lysis buffer and used for immunoblotting. As a loading control Western blotting (WB) of total cell lysate with anti-β-actin has been used. The effective serum starvation (24 h in medium without serum) and stimulation (10% FBS, 30 min) has been confirmed in WB of total cell lysates with antibodies against phosphorylated residues S240/S244 in ribosomal protein S6, which is phosphorylated by S6K1/2 (effector kinases in PI3K/mTOR pathway) in response to growth factors stimulation.

2.7. Immunoblot analysis
------------------------

Proteins were separated by SDS-PAGE, transferred onto polyvinylidene difluoride membrane, and incubated for 1 h with blocking solution (2% BSA, Tris-buffered saline, 0.1% Tween-40). After blocking the membranes were probed 2 h at 4 °C with anti-GST, anti-eEF1A (Upstate Biotechnology), anti-His tag (Cell Signalling), anti-Shp2 (Cell Signalling) or anti-pTyr 4G10 (Upstate Biotechnology) antibodies. After extensive washing with the solution of Tris-buffered saline and 0.1% Tween-40, the membranes were incubated with secondary horseradish peroxidase-conjugated antibody for 1 h at room temperature. The antigen--antibody complexes were detected using the ECL system (Millipore). When immunoblots had to be re-probed, the membranes were initially stripped and re-blocked prior to incubation with another type of primary antibody.

3. Results
==========

3.1. Existence of SH2/SH3 domain binding sites in the eEF1A1 and eEF1A2 molecules are predicted by bioinformatic analysis
-------------------------------------------------------------------------------------------------------------------------

First we examined the possibility if the 98% similar eEF1A1 and eEF1A2 might have distinct binding motifs for signalling molecules. A low stringency Scansite ([@bib28]) search revealed potential SH2/SH3 domain containing protein partners and predicted the existence of several phosphorylation sites for tyrosine kinases in both isoforms ([Fig. 1](#fig1){ref-type="fig"}). However, the SH3 recognition motif specific for Src kinase and adaptor protein Crk was found only in the eEF1A2 molecule. This is an important indication of the possibility of differential involvement of eEF1A2 in the formation of signalling complexes.

3.2. eEF1A1 and eEF1A2 interact in vitro with SH2/SH3 domains of different proteins
-----------------------------------------------------------------------------------

The ability of eEF1A1 and eEF1A2 to form complexes with SH2 and SH3 domains of different signalling molecules was directly analysed in pull down experiments. The preparative amounts of native eEF1A1 and eEF1A2 were purified from rabbit tissues as described in Section [2](#sec1){ref-type="sec"}. Importantly, the rabbit and human proteins are 100% identical. SH2 domains of signalling proteins Grb2, RasGAP, PLC-gamma1, Shc, Shp2 and SH3 domains of Crk, Csk, Fgr, Fyn, Src were expressed as recombinant proteins fused with GST, purified from bacteria, immobilized on glutathione sepharose and mixed with eEF1A1 or eEF1A2. Complexes of eEF1A1 and eEF1A2 with SH2 and SH3 domains of different proteins were detected ([Fig. 2](#fig2){ref-type="fig"}A and B). Both eEF1A1 and eEF1A2 interacted with SH2 domain of PLC-gamma1, while eEF1A2 exclusively formed complexes with SH2 domains of Grb2, RasGAP, Shc, Shp2 and SH3 domains of Crk, Fgr, Fyn, PLC-gamma1.

It should be noted that principal possibility of the interaction of PLC-gamma1 and eEF1A was shown earlier. The interactions of SH2 and SH3 domains ([@bib17]) or PH domain ([@bib9]) of PLC-gamma1 with eEF1A were reported. Our results confirmed the interaction of eEF1A with SH2 and SH3 domains of PLC-gamma1 and were used as internal positive control of interaction with known eEF1A binding partner.

Contrary to eEF1A1, eEF1A2 was found to interact with SH2/SH3 domains of several adaptor proteins. Grb2 and Shc provide a critical link between cell surface growth factor receptors and the Ras and Myc signalling pathways via interactions with cytoplasmic Tyr kinases, G-proteins and other cellular Tyr-phosphorylated proteins. Interestingly, Shc is constitutively activated (tyrosine-phosphorylated) in most breast cancer cells where non-typical expression of eEF1A2 was reported ([@bib12; @bib34]).

Identification of RasGAP protein as a direct partner of G-protein eEF1A2 may be interesting in two ways. On the one hand, RasGAP may play GTPase activating role for eEF1A2, because the initial rate of GTP hydrolysis by the intrinsic eEF1A2 GTPase is slightly lower when compared with eEF1A1 ([@bib16] and our unpublished observation). On the other hand, eEF1A2 may influence RasGAP activity and consequently modulate Ras.

eEF1A2 interacts also with SH3 domain of Crk which is involved in MAPK signalling, actin cytoskeleton reorganization and insulin receptor signalling ([@bib11]). It should be noted that eEF1A is involved in actin cytoskeleton regulation as well ([@bib14]; [@bib33]).

Fgr and Fyn are Tyr kinases that participate, in particular, in the MAPK/ERK and insulin receptor signalling pathways involved in the control of initiation of translation ([@bib2]). The interaction of eEF1A2 with SH3 domains of Fgr and Fyn suggests eEF1A2 as a prospective substrate for these enzymes.

Thus, eEF1A2 is capable of forming complexes with SH2 and SH3 domains of several signalling molecules. The potentially increased role of eEF1A2, as compared to eEF1A1, in phosphoTyr-mediated signalling pathways lends support for the putative oncogenic role assigned to eEF1A2 earlier ([@bib3; @bib18; @bib20]).

3.3. eEF1A1 and eEF1A2 are in complex with Shp2 in vivo
-------------------------------------------------------

Verification of the *in vitro* formed complexes was done *in vivo* taking as an example interaction of eEF1A with Shp2.

First, HEK 293 stable cell lines overexpressing eEF1A1-His, eEF1A2-His or GFP protein were used to confirm that endogenous Shp2 protein interacts with eEF1A2. Interestingly, specific binding of endogenous Shp2 to both isoforms of eEF1A was detected ([Fig. 3](#fig3){ref-type="fig"}A). Since only the C-terminal SH2 domain of Shp2 was used as a bait in the experiments *in vitro*, we suggest eEF1A1 and eEF1A2 bind to different domains of Shp2.

Also, a complex of endogenous eEF1A and Shp2 was immunoprecipitated from HEK293 cells using anti-eEF1A antibodies ([Fig. 3](#fig3){ref-type="fig"}B). The complex eEF1A/Shp2 was detected in growing cells. Interestingly, complex formation was more effective in cells synchronized by growth factors starvation and less efficient in cells stimulated with serum, indicating the regulatory nature of this interaction ([Fig. 3](#fig3){ref-type="fig"}B). Importantly, eEF1A2 was shown earlier to accumulate in G0 rather than in G1 and S phase cells ([@bib5]). However, since anti-eEF1A monoclonal antibodies are specific both for eEF1A1 and eEF1A2, and the presence of both isoforms in embryonic cells is possible, it is difficult to determine precisely which isoform of eEF1A interacts with Shp2 *in vivo*.

3.4. eEF1A2 and Shp2 interaction is sensitive to dephosphorylation
------------------------------------------------------------------

To test if the interaction of eEF1A2 with C-terminal SH2 domain of phosphatase Shp2 is dependent on phosphorylation status of eEF1A, equal amounts of total cell lysates of the stable cell lines expressing eEF1A1 or eEF1A2 were treated with calf intestine alkaline phosphatase, or, in control samples, incubated with phosphatase inhibitor (sodium orthovanadate). Specific interaction of SH2-Shp2 and eEF1A2 was detected only in the samples not treated with CIAP indicating that phosphorylation of eEF1A2 is a necessary condition for eEF1A2/Shp2 complex formation ([Fig. 3](#fig3){ref-type="fig"}C).

3.5. eEF1A1 and eEF1A2 are phosphorylated at Tyr in vivo
--------------------------------------------------------

The interaction of eEF1A with SH2 domains of different proteins *in vitro* as well as the eEF1A--Shp2 complexes formation *in vivo* indicate the possibility of tyrosine phosphorylation in the eEF1A molecules. To test if native eEF1A1 and eEF1A2 contain such modifications we probed the isolated eEF1A proteins with monoclonal antibodies specific to phosphorylated tyrosines (4G10). As a result, tyrosine phosphorylation of both isoforms was detected ([Fig. 4](#fig4){ref-type="fig"}A). Moreover, the phosphorylation of eEF1A1 and eEF1A2 at tyrosine residues was confirmed using the His-tagged eEF1A isoforms precipitated on Ni-NTA sepharose ([Fig. 4](#fig4){ref-type="fig"}B). The eEF1A1 and eEF1A2 samples dephosphorylated with calf intestine alcaline phosphatase were used to control specificity of 4G10 antibodies. Notably, eEF1A2 was characterized by greater phosphorylation level as compared to eEF1A1 in both experiments.

4. Discussion
=============

Besides its function in translation, eEF1A is thought to be involved in several cellular processes, including embryogenesis, senescence, oncogenic transformation, cell proliferation and organization of cytoskeleton (reviewed in [@bib14]; [@bib18; @bib20]). There are two tissue-specific isoforms of eEF1A. eEF1A1 functions in all mammalian tissues except neurons, cardiomyocytes and myotubes, where eEF1A2 is taking role and is expressed. Recently eEF1A2 was also found to express in human pancreatic islets ([@bib1]). Few attempts to differentiate the specific functions of the isoforms have been carried out so far. *In vitro*, eEF1A2 has slightly decreased translation functions \[our unpublished observation\]. Discovery of putative oncogenic role of eEF1A2 in ovarian cancer ([@bib20]) as well as opposite apoptosis-related functions of the isoforms ([@bib10]) indicated a possibility of distinct participation of eEF1A1 and eEF1A2 in cellular signalling processes. The mechanisms of cancer-related functions of eEF1A2 are not known. We suggested that difference of the isoforms could be related to their distinct ability to be involved into phosphoTyr-mediated signalling pathways.

To examine such a possibility we used the panel of cloned SH2 and SH3 domains of various signalling molecules. SH2 domains are known to associate with specific phosphoTyr-containing sites ([@bib32]). SH3 domains of adaptor proteins can support the association with a number of signalling proteins and upon cell stimulation can engage adaptor proteins with Tyr-phosphorylated cytoplasmic or membrane-attached partners ([@bib21]). As a result, we detected the interaction of eEF1A1 and eEF1A2 with SH2 domain of PLC-gamma1 indicating that both isoforms could contain phosphoTyr residues. In addition, eEF1A2 was found associated with SH2 domains of Grb2, RasGAP, Shc and Shp2 ([Fig. 2](#fig2){ref-type="fig"}A). This suggests eEF1A2 plays a more universal role in signal pathways. The finding that eEF1A2 rather than eEF1A1 can interact with SH3 domains of Crk, Fgr and Fyn supports this notion ([Fig. 2](#fig2){ref-type="fig"}B).

The association of eEF1A and Shp2 is very appealing in terms of the role Shp2 is playing in the cell-activation of Ras, with subsequent activation of PI3K and MAPK signalling pathways ([@bib24]). In addition, Shp2 regulates actin cytoskeleton reorganization by modulating the activity of small GTP-binding protein Rho ([@bib7]; [@bib15]). It is interesting that eEF1A is an actin-binding protein which can regulate actin bundling as well, but its target substrates have not been identified so far ([@bib25]). Since direct binding of eEF1A to Shp1 was recently found to have some regulatory consequence, namely eEF1A2-dependent increase of Shp1 phosphatase activity ([@bib26]) the examination of possible effect of eEF1A2 on the Shp2 activity is a tempting task for future investigations.

We have observed direct interaction of eEF1A2 with SH2 domain of RasGAP protein. Here we can only speculate about possible involvement of eEF1A2 in the activation of PI3K and MAPK pathways by Ras through RasGAP inactivation ([@bib35]). Otherwise, RasGAP may play a role of GAP for eEF1A2. The last notion could be supported by the observation that the subunits of eEF1B, regular exchange factor for eEF1A1, were not identified as interacting partners for eEF1A2 ([@bib22]).

The phosphorylation of native and overexpressed eEF1A1 and eEF1A2 at tyrosine residues was confirmed by WB with phosphotyrosine-specific antibodies ([Fig. 4](#fig4){ref-type="fig"}A and B). Several preps of eEF1A1 and eEF1A2 were analysed and eEF1A2 always demonstrated higher phosphorylation level than eEF1A1 (data not shown).

Recently, phosphorylation of Tyr 29 and Tyr 141 of eEF1A was found during an extensive search for all proteins containing phosphotyrosine in human cancer cells ([@bib31]). However, since both identified tryptic peptides contained phosphoTyr29 or phosphoTyr141 (which are identical in eEF1A1 and eEF1A2) and the overall search was limited by the peptides containing phosphotyrosine, the unambiguous identification of the phosphorylated isoform in that case was hardly possible.

Thus, we have identified several binding partners of eEF1A2 previously unknown. Novel interaction of eEF1A with tyrosine phosphatase Shp2 has been confirmed also *in vivo*. Potentially augmented ability of eEF1A2 as compared to eEF1A1 to be involved in key signal transduction complexes could be linked to the putative oncogenic role of the former found recently in ovarian cancer ([@bib4]). The definite role of eEF1A2 in activation of cell proliferation awaits further investigations.
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![Schematic representation of potential SH2 and SH3 interaction sites of eEF1A1 and eEF1A2. Predicted sites were identified by ScanSite search of eEF1A1 and eEF1A2 peptide sequences: core amino acids are indicated. Y: tyrosine kinase phosphorylation site; SH2: SH2 domain binding site; SH3: SH3 domain binding site.](gr1){#fig1}

![Interaction of eEF1A1 and eEF1A2 with different GST-SH3 and GST-SH2 domain fusion proteins. GST-SH2 (A) or GST-SH3 (B) fusion proteins were coupled to glutathione-Sepharose beads and incubated with purified eEF1A1 (upper panels in A and B) or eEF1A2 (lower panels in A and B). The beads were washed extensively and the proteins were eluted by boiling in Laemmli sample buffer. Eluted proteins were resolved by SDS-PAGE and visualized by immunoblotting with anti-eEF1A antibodies (0.2 μg of purified eEF1A1 or eEF1A2 were loaded as controls). Amount of the GST-SH2 (A) or GST-SH3 (B) fusion proteins was controlled by immunoblotting with anti-GST antibodies. As a control, non-specific binding of eEF1A1 (upper panels in A and B) or eEF1A2 (lower panels in A and B) to GST alone or to beads alone has been analysed.](gr2){#fig2}

![eEF1A1 and eEF1A2 form complexes with Shp2. (A) Complexes of His-tagged eEF1A1/eEF1A2 and Shp2 were precipitated from HEK293 stable cell lines using NiNTA sepharose. NiNTA sepharose beads were washed extensively and complexes were eluted by boiling in Laemmli sample buffer. Eluted proteins were resolved by SDS-PAGE and visualized by immunoblotting with anti-Shp2 (upper panel) or anti-His (lower panel) antibodies. NiNTA sepharose beads incubated with lysate of GFP overexpressing stable cell line were used as a control of non-specific binding of Shp2. TCL: total cell lysate. (B) Complexes were immunoprecipitated with anti-eEF1A antibodies from HEK293 cells treated under different conditions (growing, serum starved and serum starved followed by 30 min 10% serum stimulation). Protein A sepharose beads were washed extensively and the complexes were eluted by boiling in Laemmli sample buffer. Eluted proteins were resolved by SDS-PAGE and visualized by immunoblotting with anti-Shp2 antibodies. Protein A sepharose beads alone incubated with the same cell lysates were used as a control of Shp2 non-specific binding. Total cell lysates (TCL) of HEK293 cells were immunobloted with phosphospecific antibodies to phosphorylated Ser240/Thr244 in ribosomal protein S6 and β-actin to control the efficiency of treatment conditions and total protein amount used for immunoprecipitation in each sample, respectively. (C) GST or Shp2 GST-SH2 fusion proteins were coupled with glutathione-sepharose beads and incubated with phosphatase treated (10 U CIAP per 350 μg of total cell lysate) or untreated total cell lysates of stable cell lines overexpressing His-tagged eEF1A1 or eEF1A2 proteins. The beads were washed extensively and the proteins were eluted by boiling in Laemmli sample buffer. Eluted proteins were resolved by SDS-PAGE and visualized by immunoblotting with anti-His antibodies (upper panel). Amount of GST or Shp2 GST-SH2 proteins in each probe was controlled by immunoblotting with anti-GST antibodies (lower panel).](gr3){#fig3}

![eEF1A1 and eEF1A2 are phosphorylated at tyrosine residues *in vivo*. (A) 0.5 μg of purified eEF1A1 and eEF1A2 was immunobloted with anti-phosphotyrosine-specific antibodies (4G10) followed by WB with anti-eEF1A antibodies (upper panel). SDS-PAGE of purified eEF1A1 and eEF1A2 visualized by Coomassie staining, 1 μg of each protein was loaded per line (lower panel). (B) NiNTA sepharose beads with precipitated eEF1A1/eEF1A2 proteins were divided on two samples, the first was treated with 5 U CIAP at 37 °C for 1 h, second was incubated at 37 °C for 1 h in the presence of 1 mM NaOVa. NiNTA sepharose beads were washed with the lysis buffer two times; proteins were eluted by boiling in Laemmli sample buffer and resolved by SDS-PAGE. Phosphorylated eEF1A1 and eEF1A2 were visualized by immunoblotting with anti-phosphotyrosine-specific antibodies (4G10) (upper panel) followed by WB with anti-His tag antibodies (lower panel).](gr4){#fig4}
